An experimental wearable developed by U.S. researchers uses focused ultrasound to stimulate deep regions of the brain, helping participants enter REM sleep faster and remain there longer.

A soft electronic patch capable of stimulating deep areas of the brain with focused ultrasound has shown early promise as a new way of improving rapid-eye-movement sleep without medication or invasive surgery.

The experimental device, called NEUSLeeP, was developed by researchers led by the University of Texas at Austin. Designed to adhere to the skin during sleep, it combines ultrasound neuromodulation with electrodes that monitor electrical activity from the brain and surrounding muscles in real time.

In a study involving 28 participants, researchers reported that the device reduced the time required to reach REM sleep by approximately 43 minutes and increased REM duration by about 16 minutes on average.

The findings could eventually open a new technological approach to sleep medicine, an area currently dominated by behavioural therapies, pharmaceuticals and diagnostic monitoring devices.

REM sleep is associated with dreaming but also plays an important role in emotional processing, memory and the regulation of stress. Disturbances in REM patterns are associated with several sleep and neuropsychiatric conditions, making the ability to selectively influence this phase of sleep potentially significant.

What distinguishes NEUSLeeP from conventional consumer sleep wearables is that it does more than measure sleep.

Smartwatches, rings and other trackers typically monitor movement, heart rate, temperature or blood oxygen and then estimate sleep stages using software. The new patch attempts to actively alter brain activity while simultaneously measuring the body’s response.

At the centre of the system is a miniature array capable of producing transcranial focused ultrasound.

The technology directs acoustic energy through the skull toward specific neural structures. In the study, researchers targeted the subthalamic nucleus, a region deep inside the brain that has previously been associated with sleep regulation and has also been targeted through invasive deep-brain stimulation in neurological medicine.

Focused ultrasound offers a potentially important advantage: it can reach deeper brain structures without implanted electrodes.

Traditional deep-brain stimulation requires neurosurgery to place electrical leads inside the brain. NEUSLeeP, by contrast, is designed to deliver stimulation externally through a wearable platform weighing approximately 103 grams.

The patch also contains multiple electrophysiological sensors capable of recording signals normally used in laboratory sleep studies, including electroencephalography, eye movement and muscle activity.

That combination allows the system to determine sleep state and apply stimulation while the wearer remains asleep.

Researchers found that targeted stimulation increased the proportion of time participants spent in REM sleep by approximately 4.6 percentage points while producing no significant changes in the other major sleep stages.

The device also produced changes in heart-rate variability among healthy participants, according to the research team. Functional brain imaging detected alterations in activity within neural circuits associated with emotional processing.

Those findings have encouraged researchers to investigate whether improving REM sleep could eventually influence stress resilience, mood and other aspects of mental health.

The implications could extend beyond conventional sleep disorders.

Poor or fragmented sleep is increasingly associated with cardiovascular disease, metabolic disorders, cognitive decline and mental-health conditions. A wearable capable of modifying specific stages of sleep could therefore represent an entirely different category of medical technology.

Instead of administering a chemical throughout the body, future systems could potentially intervene selectively in a neural circuit only when required.

That concept is part of a broader movement toward closed-loop neuromodulation.

In a closed-loop device, sensors continuously assess biological activity and software determines when stimulation should be delivered. The resulting response can then be measured immediately, allowing the system to adjust its behaviour.

Similar principles are increasingly being explored in treatments for epilepsy, Parkinson’s disease, chronic pain and psychiatric disorders.

Sleep could become another major application.

NEUSLeeP is particularly notable because the researchers designed it for use during natural overnight sleep rather than only under tightly controlled laboratory conditions.

The soft adhesive construction is intended to remain attached despite normal movement, while specialised hydrogel electrodes maintain contact with the skin over extended periods.

Participants generally reported that the system was comfortable, and the researchers reported minimal adverse effects during the study.

Significant questions nevertheless remain before the technology could become a medical product.

The study was small, involving only 28 participants, and larger controlled trials will be required to determine how consistently the system performs across different ages and medical conditions.

Long-term safety will also need to be established.

Although focused ultrasound is being investigated widely as a non-invasive neuromodulation technology, repeated stimulation of deep neural structures over months or years would require rigorous evaluation.

Researchers will also need to determine which patients would benefit most.

Someone experiencing insomnia, for example, may have a very different neurological sleep problem from a patient with depression, post-traumatic stress disorder, narcolepsy or REM sleep behaviour disorder.

Increasing REM sleep indiscriminately would therefore not necessarily be appropriate for every user.

The technology also remains very different from a consumer sleep tracker.

There is currently no indication that the experimental patch is ready for routine home use or commercial sale, and the reported results should be viewed as early-stage clinical research rather than evidence of an approved treatment.

Nevertheless, the project illustrates how rapidly wearable medical technology is evolving.

Devices worn on the body are increasingly shifting from passive observation toward active treatment.

Wearable injectors can already deliver medicines automatically. Continuous glucose monitors provide near-real-time metabolic information. Electrical stimulation systems can influence nerves and muscles.

Focused-ultrasound wearables could extend that evolution directly into the brain.

For the medical-device industry, the prospect is particularly important because sleep represents an enormous potential market.

Millions of people rely on prescription drugs, over-the-counter supplements or behavioural interventions to manage sleep problems, while consumer demand for watches, rings and mattresses capable of tracking sleep has grown rapidly.

A device capable not merely of telling users how they slept but of selectively improving particular stages would represent a fundamentally different proposition.

The University of Texas researchers emphasise that further development is required, but they see the technology as a possible platform for studying and ultimately treating sleep disorders outside specialist laboratories.

If larger trials confirm the initial results, the most significant aspect of NEUSLeeP may therefore not be the extra minutes of REM sleep observed in the first study.

It may be the demonstration that a lightweight device attached to the skin can monitor the sleeping brain and simultaneously reach deep enough inside it to alter its activity.

That could mark an important step toward a new generation of therapeutic wearables — devices that do not simply record what the human body is doing, but actively intervene when something needs to change.